Back to top
more

Guardant Health (GH)

(Real Time Quote from BATS)

$64.82 USD

64.82
646,690

+1.32 (2.08%)

Updated Aug 28, 2025 02:42 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 35% (159 out of 245)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

TMO Receives FDA Approval for Oncomine Dx Target Test

by Zacks Equity Research

Thermo Fisher secures FDA approval for its Oncomine Dx Target Test to identify NSCLC patients eligible for HERNEXEOS treatment.

Sridatri Sarkar headshot

TEM Once Again Raises Its 2025 Sales Guidance: What's Driving the Move?

by Sridatri Sarkar

Tempus AI raises 2025 revenue outlook again after strong Q2 growth in genomics and AI-driven oncology solutions.

Zacks Equity Research

Guardant Health (GH) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

Although the revenue and EPS for Guardant Health (GH) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Equity Research

Guardant Health (GH) Reports Q2 Loss, Beats Revenue Estimates

by Zacks Equity Research

Guardant Health (GH) delivered earnings and revenue surprises of +15.38% and +9.77%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Sridatri Sarkar headshot

Tempus AI Taps Growing ICI Market With New xM Assay

by Sridatri Sarkar

TEM launches xM, a liquid biopsy assay to monitor real-time response to ICI therapy in advanced solid tumors.

Urmimala Biswas headshot

Tempus AI Revenues & Profit Rise: What to Expect Ahead of Q2 Release

by Urmimala Biswas

TEM's revenue and gross profit are climbing fast as new AI tools and data services boost margins ahead of Q2 earnings.

Urmimala Biswas headshot

TEM vs. GH: Which AI in Precision Oncology Stock Has More Upside Now?

by Urmimala Biswas

GH gains ground with stronger guidance, improving margin and Reveal's breakout as TEM scales fast but stays unprofitable.

Moumi Mondal headshot

Tempus AI's 89% Genomics Surge: Will the Momentum Keep Building?

by Moumi Mondal

TEM's Genomics revenues soar 89% on oncology test gains and Ambry Genetics' boost. New assays could fuel more growth.

Moumi Mondal headshot

Tempus AI Eyes Positive Adjusted EBITDA in 2025: Is It Taking Shape?

by Moumi Mondal

TEM's rapid growth and cost discipline are paving the way for a positive adjusted EBITDA in 2025.

Zacks Equity Research

Is First Trust Mid Cap Growth AlphaDEX ETF (FNY) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for FNY

Zacks Equity Research

Guardant Health (GH) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Guardant Health (GH) delivered earnings and revenue surprises of 19.67% and 6.47%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Repligen (RGEN) Tops Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Repligen (RGEN) delivered earnings and revenue surprises of 11.43% and 2.85%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Amgen (AMGN) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Amgen (AMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Earnings Preview: Guardant Health (GH) Q1 Earnings Expected to Decline

by Zacks Equity Research

Guardant Health (GH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises

by Zacks Equity Research

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Zacks Equity Research

Is Guardant Health (GH) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Guardant Health (GH) and Brookdale Senior Living (BKD) have performed compared to their sector so far this year.

Zacks Equity Research

Guardant Health (GH) Reports Q4 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

The headline numbers for Guardant Health (GH) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks Equity Research

Guardant Health (GH) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Guardant Health (GH) delivered earnings and revenue surprises of -24% and 0.98%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Will Fate Therapeutics (FATE) Report Negative Q4 Earnings? What You Should Know

by Zacks Equity Research

Fate Therapeutics (FATE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Exploring Analyst Estimates for Guardant Health (GH) Q4 Earnings, Beyond Revenue and EPS

by Zacks Equity Research

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Guardant Health (GH), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2024.

Zacks Equity Research

Guardant Health (GH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Guardant Health (GH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

by Zacks Equity Research

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Zacks Equity Research

Here's Why Guardant Health (GH) Is a Great 'Buy the Bottom' Stock Now

by Zacks Equity Research

After losing some value lately, a hammer chart pattern has been formed for Guardant Health (GH), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Zacks Equity Research

Are Medical Stocks Lagging Guardant Health (GH) This Year?

by Zacks Equity Research

Here is how Guardant Health (GH) and Alnylam Pharmaceuticals (ALNY) have performed compared to their sector so far this year.

Zacks Equity Research

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises

by Zacks Equity Research

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.